# US 5,708,013 A · Pyridine derivative and therapeutic agent for ulcer comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,708,013 A
- Document ID: US5708013A
- Status: Granted
- Kind: A
- Application number: 08/524,109
- Filed: 1995-08-21
- Granted: 1998-01-13
- Earliest claimed: 1987-06-19
- Assignees: Eisai Co., Ltd.
- Inventors: Shigeru Souda; Norihiro Ueda; Shuhei Miyazawa; Katsuya Tagami; Seiichiro Nomoto; Makoto Okita; Naoyuki Shimomura; Toshihiko Kaneko; Masatoshi Fujimoto; Manabu Murakami; Kiyoshi Oketani; Hideaki Fujisaki; Hisashi Shibata; Tsuneo Wakabayashi
- Web page: https://patentgrep.com/patent/US5708013A

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A pyridine compound having the formula is disclosed and useful to treat the peptic ulcer. ##STR1## wherein R.sup.1 and R.sup.2 which may be the same or different are each a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogenated lower alkyl group, or a halogen atom, R.sup.3 and R.sup.4 which may be the same or different are each a hydrogen atom or a lower alkyl group, X is a group represented by the formula --S--, a group represented by the formula ##STR2## or a group represented by the formula ##STR3## and n is an integer of 1 to 6, provided that R.sup.3 and R.sup.4 are not simultaneously hydrogen atoms when n is 1.

## Claims

### Claim 1

A compound of the formula: ##STR61## wherein R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, lower alkoxy, halogen, or halogenated lower alkyl, and the pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein R.sup.1 is methoxy and R.sup.2 is hydrogen.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein R.sup.1 and R.sup.2 are both hydrogen.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein R.sup.1 is CF.sub.3 and R.sup.2 is hydrogen.

### Claim 5 (depends on 1)

A compound as claimed in claim 1 wherein R.sup.1 is methyl and R.sup.2 is hydrogen.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 wherein R.sup.1 is chlorine and R.sup.2 is hydrogen.

### Claim 7

A compound selected from the group consisting of:
2-›4-{(2-butoxy)ethoxy}-3-methylpyridin-2-yl!methylsulfinyl-5-methoxy-1H-be nzimidazole;
2-›4-{(2-butoxy)ethoxy}-3-methylpyridin-2-yl!methylsulfinyl-5-trifluorometh yl-1H-benzimidazole;
2-›4-{(2-butoxy)ethoxy}-3-methylpyridin-2-yl!methylsulfinyl-5,6-dimethyl-1H -benzimidazole, and
2-›4-{(2-butoxy)ethoxy}-3-methylpyridin-2-yl!methylsulfinyl-5-chloro-1H-ben zimidazole.

### Claim 8

A pharmaceutical composition comprising together with a pharmaceutically acceptable carrier an effective amount of a compound of the formula: ##STR62## wherein R1 and R2 are independently hydrogen, lower alkyl, lower alkoxy, halogen or, halogenated lower alkyl, and the pharmaceutically acceptable salt thereof.

### Claim 9

A method of treating peptic ulcers comprising administering to a person suffering therefrom an effective amount of a compound of the formula: ##STR63## wherein R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, lower alkoxy, halogen or halogenated lower alkyl, and the pharmaceutically acceptable salt thereof.